公开(公告)号：US20210238605A1

公开(公告)日：2021-08-05

申请号：US16972152

申请日：2019-06-14

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  UNIVERSITY COLLEGE LONDON ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE ,  UNIVERSITÉ DE CAEN NORMANDIE ,  CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE CAEN

发明人： Marie-Pierre GRATACAP ,  Jean DARCOURT ,  Bart VANHAESEBROECK ,  Gaëtan CHICANNE ,  Bernard PAYRASTRE ,  Vincent LARRUE ,  Romain SOLINHAC ,  Aude JAFFRE ,  Denis VIVIEN ,  Typhaine ANQUETIL

IPC分类号： C12N15/113 ,  A61P9/10 ,  G01N33/50

摘要： Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an pot ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For NI instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2β reduces cerebral infarction in two ischemia/reperfusion (UR) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation. Accordingly, the present invention relates to a method for the preservation of vascular endothelial cell barrier integrity in a patient in need thereof comprising administering to the subject a therapeutically effective amount of a PI3KC2β inhibitor.

公开(公告)号：US20230287430A1

公开(公告)日：2023-09-14

申请号：US18055597

申请日：2022-11-15

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  UNIVERSITY COLLEGE LONDON ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE ,  UNIVERSITÉ DE CAEN NORMANDIE ,  CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE CAEN

发明人： Marie-Pierre GRATACAP ,  Jean DARCOURT ,  Bart VANHAESEBROECK ,  Gaëtan CHICANNE ,  Bernard PAYRASTRE ,  Vincent LARRUE ,  Romain SOLINHAC ,  Aude JAFFRE ,  Denis VIVIEN ,  Typhaine ANQUETIL

IPC分类号： C12N15/113 ,  A61P9/10 ,  G01N33/50

CPC分类号： C12N15/1137 ,  A61P9/10 ,  G01N33/5064 ,  C12N2310/14 ,  C12N2310/531

摘要： Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2β reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood—brain barrier (BBB) after ischemic stroke and reduces inflammation. Accordingly, the present invention relates to a method for the preservation of vascular endothelial cell barrier integrity in a patient in need thereof comprising administering to the subject a therapeutically effective amount of a PI3KC2β inhibitor.